Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Sea Limited (SE) Price & Performance

Merck & Co., Inc.Trade
Sea LimitedTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Sea Limited — how do they compare? Merck & Co., Inc. trades at $129.94 (market cap $321.77B), while Sea Limited trades at $130.4 (market cap $80.55B). The key difference: Merck & Co., Inc. is far larger — about 4× Sea Limited's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Sea Limited pays none. Which is the better fit depends on your goals.

MRKSE
Market Cap
$321.77B$80.55B
Sector
HealthMedia
52-Week High
$131.84$196.50
52-Week Low
$77.60$78.16
Enterprise Value
$368.53B$75.58B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Sea Limited

Sea Limited (SE) trades at $114.80, up 1.21% with strong technical momentum as the stock approaches key resistance levels. The company demonstrates robust fundamental growth with Q2 2026 revenue of $7.8 billion (up 48% YoY) and net income growth of 11%, supported by diversified performance across e-commerce, fintech, and gaming segments. Analyst consensus remains strongly bullish with a $128.33 price target, though valuation metrics appear elevated with a P/E of 50.78.

SE presents compelling growth prospects with accelerating revenue and expanding profitability, but faces risks from increased investment spending and competitive pressures. The stock's current technical overbought condition near resistance suggests potential near-term consolidation before further upside. Wall Street's overwhelming buy rating (70% of analysts) supports the positive long-term outlook despite premium valuation concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Sea Limited

Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.

Read more on SE